23andMe to Report FY2024 First Quarter Financial Results
25 juil. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
20 juil. 2023 09h23 HE
|
23andMe, Inc.
23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, with medication insights Lipid-lowering statins are one of the most commonly...
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
21 juin 2023 07h00 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part...
23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results
25 mai 2023 16h05 HE
|
23andMe, Inc.
Achieved FY2023 financial guidance FY2023 full year revenue grew 10% over prior year Webcast today, May 25, 2023 at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., May 25, 2023 (GLOBE...
New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture
16 mai 2023 07h00 HE
|
23andMe, Inc.
66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said...
23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results
11 mai 2023 16h05 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report...
23andMe Releases New Report Revealing Likelihood of Developing Lupus
09 mai 2023 07h00 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on...
Reza Afkhami Joins 23andMe as Chief Corporate Development Officer
08 mai 2023 07h00 HE
|
23andMe Holding Co.
SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of...
23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
14 avr. 2023 16h05 HE
|
23andMe Holding Co.
First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral...
Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program
11 avr. 2023 07h00 HE
|
23andMe Holding Co.
Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between...